Journal
NUTRITION IN CLINICAL PRACTICE
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/ncp.11015
Keywords
adults; intestinal failure; intestinal transplantation; intravenous supplementation; parenteral nutrition; short bowel syndrome; teduglutide
Categories
Ask authors/readers for more resources
Short bowel syndrome (SBS) is a rare gastrointestinal disorder associated with intestinal failure (SBS-IF) and poor health-related outcomes. Patients with SBS-IF require long-term intravenous supplementation (IVS) and the goal of treatment is to reduce or eliminate the need for IVS. Teduglutide, a glucagon-like peptide 2 analog, has been shown to be effective in reducing IVS dependence and improving the quality of life for SBS-IF patients. The management of SBS-IF patients is complex and requires close monitoring.
Short bowel syndrome (SBS) is a rare gastrointestinal disorder associated with intestinal failure (SBS-IF) and poor health-related outcomes. Patients with SBS-IF are unable to absorb sufficient nutrients or fluids to maintain significantly metabolic homeostasis via oral or enteral intake alone and require long-term intravenous supplementation (IVS), consisting of partial or total parenteral nutrition, fluids, electrolytes, or a combination of these. The goal of medical and surgical treatment for patients with SBS-IF is to maximize intestinal remnant absorptive capacity so that the need for IVS support may eventually be reduced or eliminated. Daily subcutaneous administration of the glucagon-like peptide 2 analog, teduglutide, has been shown to be clinically effective in reducing IVS dependence and potentially improving the health-related quality of life of patients with SBS-IF. The management of patients with SBS-IF is complex and requires close monitoring. This narrative review discusses the use of teduglutide for patients with SBS-IF in clinical practice. The screening of patient eligibility for teduglutide treatment, initiation, monitoring of efficacy and safety of treatment, adapting or weaning off IVS, and the healthcare setting needed for SBS-IF management are described, taking into consideration data from clinical trials, observational studies, and clinical experience.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available